Home » Newsletters » BioWorld Science

BioWorld Science

July 4, 2014

View Archived Issues

CTI BioPharma completes enrollment in phase III myelofibrosis trial of pacritinib

GlycoVaxyn and Janssen initiate phase I trial of extra-intestinal pathogenic E. coli vaccine

Cortex Pharmaceuticals enters an agreement with the University of Illinois

PaxVax reports efficacy results from phase III cholera challenge study

Embera's phase I study of EMB-001 to receive funding from Sounds Affects Life

Novel radiotracer shows potential for PET imaging of LPA-1 receptor expression

Renal benefits reported for VPI-2690B in a model of diabetic nephropathy

Ultragenyx initiates pediatric X-linked hypophosphatemia trial for KRN-23

Presentation of data on Aeolus' AEOL-10150 medical countermeasure

DGAT1 inhibitor protects beta-cell function under nutrient overload

TH-302 enters phase II trial in NSCLC

Enrollment opens in trial of apatorsen and chemotherapy in squamous cell lung cancer

Quark completes study of QPI-1002 to prevent delayed graft function in kidney transplantation

First-in-human evaluation of the safety of an antibody against kidney transplant rejection

Roche prepares new proteasome inhibitors

Researchers at Chiesi Farmaceutici disclose novel PDE4 inhibitors

Antiviral agents patented by Siga Technologies

Japanese researchers divulge novel anti-VASH2 antibodies for cancer

Merck & Co. prepares new HIV vaccines

PKC, a potential target for NAFLD-related hepatic insulin resistance in type 2 diabetes

FDA places clinical hold on phase I trial of TKM-Ebola

FDA grants orphan drug designation to trifarotene for congenital ichthyosis

Eagle Pharmaceuticals gains tentative approval for patented bendamustine injection

First patient enrolled in the PROSPECT II study

FDA approves belinostat for peripheral T-cell lymphoma

Halaven approved in the E.U. for second-line therapy of breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 3, 2026